In the 15th and final chapter of its series on Johnson & Johnson’s Risperdal (risperidone), the Huffington Post (10/2) “Highline” recounts how the jury in the Pledger case handed down its verdict Feb. 24, 2015, finding J&J was negligent by failing to provide an adequate warning about the risk of […]
Supreme Court
2 posts
By Buck Daniel March 20, 2013 – Two years ago, the Supreme Court severely limited the conditions under which consumers could sue generic drug manufacturers. The Pliva v. Mensing decision stated that generic manufacturers do not have control over a drug’s warning label content due to FDA regulations; and therefore, […]